Travere Therapeutics swings to Q3 net loss of $52.34 million
Bitget2026/11/02 21:04- Travere Therapeutics swung to a third-quarter 2026 net loss of $52.34 million from a year-earlier profit of $25.71 million.
- Total revenue rose 36% year-over-year to $224.56 million.
- An in-process research and development expense of $113.1 million resulted from closing the Everest Medicines licensing agreement for civorebrutinib.
- Pegtibatinase Phase 3 HARMONY results remain expected in second-half 2027; civorebrutinib U.S. IND submission is planned by year-end 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
Crypto prices
More
